Emerging Keytruda Litigation
Keytruda (pembrolizumab) made by Merck Sharpe Dohme first received FDA approval pursuant to Biologic License Application (BLA: 125514) in September of 2014.
Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Keytruda when combined with other medications indicated for the treatment of multiple myeloma may cause death in some patients according to federal drug regulators.
Two post approval clinic trials, Keynote-185 and Keynote-185 resulted in a significant number of deaths among patients participating in the studies.
Learn More About the Emerging Keytruda Litigation
The emerging Keytruda Litigation will be used as a case study in the May 18 – 21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Couse, contact Jenny Levine at firstname.lastname@example.org or call (954) 520-4494.
For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”
Course attendees will receive the benefit of a step by step analysis of the emerging Keytruda Litigation, using these primary metrics:
Some of the top mass tort trial lawyers in the country have endorsed the Mass Tort Nexus Immersion Course>
The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively. Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.